Keyphrases
Chimeric Antigen Receptor T Cells (CAR-T)
100%
Hematopoietic Stem Cells
54%
Acute Myeloid Leukemia
40%
T Cells
35%
CAR T-cell Therapy
32%
Interleukin-7 (IL-7)
32%
Natural Killer Cells
25%
Chimeric Antigen Receptor T-cell Therapy
21%
Melphalan
21%
CD33
21%
Recombinant Human interleukin-7
20%
T-cell Malignancies
19%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
18%
Rhesus Macaque
18%
Cancer Immunotherapy
17%
Nonlinear Signal
16%
Prednisone
16%
Multiple Myeloma
16%
Maintenance Therapy
16%
EphB4
16%
Hybrid Fc
16%
Lenalidomide Maintenance
16%
Invisible
16%
Off-target Sites
16%
CIRCLE-seq
16%
Universal CAR-T
16%
Anti-Jka
16%
Normal Hematopoiesis
16%
Pharmacoeconomics
16%
Immune Environment
16%
Macrophages
16%
MHC Class II
16%
Off-target Editing
16%
Adjuvant Therapy
16%
T Cell Immunotherapy
16%
Natural Killer
16%
Human Epidermal Growth Factor Receptor 2 (HER2)
16%
MHC Class II Expression
16%
Genetic Inactivation
16%
Immune Adjuvant
16%
Therapeutic Target
16%
Antitumor Activity
16%
In Silico Prediction
16%
ABO Incompatibility
16%
Leukemia Cells
16%
Cell Survival
16%
Mass Cytometry
16%
Acute Myeloid Leukemia Cells
16%
T Cell Expansion
16%
Mucormycosis
16%
Immunology and Microbiology
Chimeric Antigen Receptor T-Cell
72%
T Cell
69%
Hematopoietic Stem Cell
49%
Myeloid
49%
Interleukin 7
35%
Chimeric Antigen Receptor
34%
Immunotherapy
34%
Leukemia Cell
32%
Natural Killer Cell
23%
Chimeric Antigen Receptor T-Cell Therapy
21%
CD33
21%
Rhesus Monkey
18%
Mass Cytometry
16%
CD2
16%
Aplastic Anemia
16%
Computer Model
16%
Cell Survival
16%
Flotetuzumab
16%
Macrophage
16%
Recombinant Interleukin 7
16%
Histocompatibility
16%
MHC Class II
16%
Cancer Immunotherapy
16%
CD7
16%
Blood Group ABO Incompatibility
16%
Cell Expansion
16%
Hematopoietic Stem Cell Transplantation
16%
Allogeneic Hematopoietic Stem Cell Transplantation
16%
Antineoplastic Activity
16%
Immunity
16%
Immune System
15%
Adjuvant
13%
Monospecific Antibody
12%
Cytokine
12%
Hemocyte
11%
Mouse Model
10%
Xenograft
8%
Delayed Hemolytic Transfusion Reaction
8%
Blood Group AB
8%
Blood Group O
8%
Stem Cell
8%
Peripheral Blood Stem Cell
8%
Rituximab
8%
Conditioning
8%
Stem Cell Transplant
8%
Antigen Specificity
7%
Surface Property
7%
Hematopoietic Cell
6%
CRISPR/Cas9
6%
CD19
6%
Medicine and Dentistry
Chimeric Antigen Receptor
40%
Chimeric Antigen Receptor T-Cell
40%
Hematopoietic Stem Cell
32%
Acute Myeloid Leukemia
32%
Interleukin 7
32%
Chimeric Antigen Receptor T-Cell Immunotherapy
21%
Melphalan
21%
Neoplasm
17%
Mucormycosis
16%
Leukemia Cell
16%
Aplastic Anemia
16%
Antifungal Agent
16%
Blood Group ABO Incompatibility
16%
Maintenance Therapy
16%
Epidermal Growth Factor Receptor
16%
Macrophage
16%
Lenalidomide
16%
Hematopoiesis
16%
Recombinant Interleukin 7
16%
Adjuvant Therapy
16%
Gamma Urogastrone
16%
Health Care Cost
16%
Cell Survival
16%
Multiple Myeloma
16%
Cancer Immunotherapy
16%
Breast Cancer
16%
Cell Expansion
16%
Allogeneic Hematopoietic Stem Cell Transplantation
16%
Antineoplastic Activity
16%
Hematopoietic Stem Cell Transplantation
16%
Natural Killer Cell
16%
Adjuvant
13%
Prednisone
13%
Adverse Event
10%
Cytokine
9%
Antigen Specificity
8%
Hematologic Malignancy
8%
Protein Function
8%
Blood Group AB
8%
Blood Group O
8%
Progression Free Survival
8%
Amino Acid
8%
Cancer Cell
8%
Target Protein
8%
Receptor Binding
8%
Hematopoietic Stem Cell
8%
Erythrocyte
8%
Conditioning
8%
Rituximab
8%
Stem Cell Transplant
8%
